54 results
8-K
EX-99.1
INM
InMed Pharmaceuticals Inc
29 Nov 23
Regulation FD Disclosure
2:50pm
pipeline to treat both front of eye and back of eye indications, including AMD,” said Dr. Eric Hsu, SVP of Preclinical R&D at InMed.
From previous ocular
424B3
INM
InMed Pharmaceuticals Inc
13 Nov 23
Prospectus supplement
5:05pm
Candidates;
Our ability to commercialize and, where required, register products in the pharmaceutical R&D programs (“Product Candidates”) and those targeted
8-K
EX-99.1
98bdj
24 Oct 23
Regulation FD Disclosure
4:18pm
8-K
EX-99.1
134ia4carw9z107e3p
20 Jul 23
Regulation FD Disclosure
2:18pm
8-K
EX-99.1
sb1fsf8ccfaguyfwvnmk
22 Jun 23
InMed Pharmaceuticals Inc. Announces Results from a Phase 2 Clinical Trial in Epidermolysis Bullosa
4:28pm
424B3
h05 sf2esp5io0
19 Oct 22
Prospectus supplement
6:10am
8-K
EX-99.1
cdwzf253bs 7d00m0y
23 Sep 22
InMed Pharmaceuticals Reports Full Year Fiscal 2022 Financial Results and Provides Business Update
4:53pm
8-K
EX-99.1
r8rukfb laos1
8 Sep 22
InMed Pharmaceuticals Provides Update on its Core Research and Development Programs and BayMedica Business
4:02pm
8-K
mtw54n3g3
8 Sep 22
InMed Pharmaceuticals Provides Update on its Core Research and Development Programs and BayMedica Business
4:02pm